Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

European Journal of Cancer

Volumn 70, Issue , 2017, Pages 146-155

  Miles, David ^a   Cameron, David ^b   Bondarenko, Igor ^c   Manzyuk, Lyudmila ^d   Alcedo, Juan Carlos ^e   Lopez, Roberto Ivan ^f   Im, Seock Ah ^g   Canon, Jean Luc ^h   Shparyk, Yaroslav ⁱ   Yardley, Denise A ^j   Masuda, Norikazu ^k   Ro, Jungsil ^l   Denduluri, Neelima ^m   Hubeaux, Stanislas ⁿ   Quah, Cheng ^o   Bais, Carlos ^o   O'Shaughnessy, Joyce ^p  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Dnipropetrovsk State Medical Academy   (Ukraine)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e Centro Hemato Oncologico Paitilla   (Panama)

^f National Oncology Institute   (Panama)

^g Seoul National University Hospital   (South Korea)

^h Grand Hopital de Charleroi   (Belgium)

ⁱ Chemotherapy Department   (Ukraine)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k OSAKA NATIONAL HOSPITAL   (Japan)

^l National Cancer Center   (South Korea)

^m Virginia Cancer Specialists PC   (United States)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

^o GENENTECH INC   (United States)

^p BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Bevacizumab; Biomarker; Double blind; Metastatic breast cancer; Predictive; Prospective; VEGF A; Weekly paclitaxel

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; PACLITAXEL; PLACEBO; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; EPISTAXIS; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSORY NEUROPATHY; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PACLITAXEL; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 85006136818     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.09.024     Document Type: Article

References (22)

1. [1] Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007), 2666–2676.
2. [2] Miles, D.W., Chan, A., Dirix, L.Y., Cortés, J., Pivot, X., Tomczak, P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28 (2010), 3239–3247.
3. [3] Robert, N.J., Diéras, V., Glaspy, J., Brufsky, A.M., Bondarenko, I., Lipatov, O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 29 (2011), 1252–1260.
4. [4] Gray, R., Bhattacharya, S., Bowden, C., Miller, K., Comis, R.L., Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27 (2009), 4966–4972.
5. [5] Gligorov, J., Richard, S., Weekly paclitaxel—still preferred first-line taxane for mBC. Nat Rev Clin Oncol 12 (2015), 508–509.
6. [6] Miles, D.W., Diéras, V., Cortés, J., Duenne, A.A., Yi, J., O'Shaughnessy, J., First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24 (2013), 2773–2780.
7. [7] Lambrechts, D., Lenz, H.J., de Haas, S., Carmeliet, P., Scherer, S.J., Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31 (2013), 1219–1230.
8. [8] Maru, D., Venook, A.P., Ellis, L.M., Predictive biomarkers for bevacizumab: are we there yet?. Clin Cancer Res 19 (2013), 2824–2827.
9. [9] Hegde, P.S., Jubb, A.M., Chen, D., Li, N.F., Meng, Y.G., Bernaards, C., et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19 (2013), 929–937.
10. [10] Miles, D.W., de Haas, S.L., Dirix, L.Y., Romieu, G., Chan, A., Pivot, X., et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108 (2013), 1052–1060.
11. [11] Van Cutsem, E., de Haas, S., Kang, Y.K., Ohtsu, A., Tebbutt, N.C., Ming Xu, J., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30 (2012), 2119–2127.
12. [12] Van Cutsem E, Jayson G, Dive C, Dilba P, de Haas S, Wild N, et al. Analysis of blood plasma factors in the AVITA phase III randomized study of bevacizumab (bev) with gemcitabineerlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC). Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, 23e27 September 2011. Abstr. 803.
13. [13] Rugo, H.S., Barry, W.T., Moreno-Aspitia, A., Lyss, A.P., Cirrincione, C., Leung, E., et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 33 (2015), 2361–2369.
14. [14] Lang, I., Brodowicz, T., Ryvo, L., Kahan, Z., Greil, R., Beslija, S., et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 14 (2013), 125–133.
15. [15] Verrill, M.W., Lee, J., Cameron, D.A., Agrawal, R., Coleman, R.E., McAdam, K., et al. Anglo-Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol, 25(Suppl.), 2007, 18s Abstr. LBA1005.
16. [16] Robert, N., Loesch, D., Lindquist, D., Ratnam, S., Hyman, W., Whittaker, T., et al. A randomized, phase II trial of weekly paclitaxel versus weekly paclitaxel+carboplatin for first-line metastatic breast cancer. Breast Cancer Res Treat(Suppl.), 2003, S129 Abstr. 534.
17. [17] Seidman, A.D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P.K., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26 (2008), 1642–1649.
18. [18] Martin, M., Roche, H., Pinter, T., Crown, J., Kennedy, M.J., Provencher, L., et al. TRIO 010 investigators. motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12 (2011), 369–376.
19. [19] Bais, C., Rabe, C., Wild, N., Swiatek-de Lange, M., Chen, D., Hong, K., et al. Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications). J Clin Oncol, 32(Suppl.), 2014, 5s Abstr. 3040.
20. [20] de Haas, S., Delmar, P., Bansal, A.T., Moisse, M., Miles, D.W., Leighl, N., et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 17 (2014), 909–920.
21. [21] Roche data on file. Avastin biomarker report to the European Medicines Agency, June 2015. Biomarker ANX 068.2.
22. [22] Cortes, J., Calvo, V., Ramírez-Merino, N., O'Shaughnessy, J., Brufsky, A., Robert, N., et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 23 (2012), 1130–1137.